PGx sample

Pharmacogenetics Sample report

DISCLAIMER

THIS REPORT HAS BEEN GENERATED BY A COMPUTER PROGRAM AND IS NOT INTENDED TO PROVIDE MEDICAL ADVICE. THE INFORMATION PROVIDED IS FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT RECOMMENDATIONS. IF YOU HAVE ANY QUESTIONS OR CONCERNS ABOUT YOUR HEALTH, PLEASE CONSULT YOUR HEALTHCARE PROVIDER.

Guide to Your Personalized Medication Response Report

This report is designed to help you understand how your unique genetic makeup may influence your response to various medications. It is divided into several sections to provide a comprehensive overview of how specific genetic variations in your DNA may affect your health and treatment options.

Explanation of Drug Metabolism and Metabolizer Enzymes

What You’ll Learn

• How your body uses special proteins called enzymes to process medications.
• An introduction to drug metabolism, the process by which your body breaks down and removes medications.
• How genetic differences in these enzymes can affect the way medications work for you, including their effectiveness and the risk of side effects.

Variants Impacting Cardiovascular Drugs

What You’ll Learn

• How certain genetic variations may influence your response to medications related to heart health and blood pressure control.
• Detailed information on specific genes such as CYP2C9, CYP4F2, and KIF6.
• Personalized insights into how these genetic factors may require adjustments in medication types or dosages.

Variants Impacting Mental Health and Pain Drugs

What You’ll Learn

• The impact of your genetic variations on medications used for mental health conditions and pain management.
• An exploration of genes like OPRM1, SCN1A, and CYP2C19.
• How these genetic factors may affect the effectiveness of certain antidepressants, pain relievers, and treatments for addiction.

Variants Impacting Immunity and Inflammation-Related Drugs

What You’ll Learn

• How your genetics may influence your response to medications used for immune system conditions and inflammation.
• Insights into genes such as NAT2, ATIC, and SLCO1B1.
• Potential implications for treatments related to conditions like tuberculosis and rheumatoid arthritis.

Potential Nutraceuticals Based on Your Genetic Variations

What You’ll Learn

• An overview of dietary supplements or nutraceuticals that may be beneficial for you based on your genetic makeup.
• Information on natural compounds that could support your health, considering your specific gene mutations.
• Emphasis on the importance of consulting a healthcare professional before adding any supplements to your regimen.

How to Use This Report

• Review Each Section Carefully: Understand how your genetics may affect different types of medications and what that means for your health.
• Personalized Insights: Pay attention to the specific recommendations and insights provided for your genetic variations.
• Share with Your Healthcare Provider: Use this report as a tool to discuss potential medication adjustments or considerations with your doctor or pharmacist.
• Ask Questions: If there’s anything you’re unsure about, don’t hesitate to seek clarification from a healthcare professional.

Note: This report is intended for informational purposes only and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider before making any changes to your medications or supplements.

Explanation of How Your Body Processes Medications

Your body uses special proteins called enzymes to break down medications so they can work properly and be removed from your body. This process is called metabolism. Think of enzymes as tiny helpers that process medicines.

Sometimes, differences in your genes can affect how well these enzymes work. This can change how your body handles certain medications, affecting how well they work for you and whether you might have side effects.

1. CYP2C9 Enzyme

What Does It Do?

The CYP2C9 enzyme helps your body process (metabolize) certain medications, especially some used for pain relief and blood thinning.

Your Genetic Variation

You have a version of the gene (rs1799853 with CT genotype) that makes the CYP2C9 enzyme work slower than normal.

What This Means for You

Warfarin (a blood thinner):

• Effect: Your body breaks down warfarin more slowly. This means the medicine can build up in your body, increasing the risk of bleeding.
• What to Do: Your doctor may start you on a lower dose and monitor your blood clotting levels closely to ensure safety.

Pain Relievers (like Celecoxib and Ibuprofen):

• Effect: Slower processing can lead to higher levels of the medicine in your body, increasing the chance of side effects like stomach upset or bleeding.
• What to Do: Your doctor may recommend a lower dose or consider alternative medications.

2. CYP2C19 Enzyme

What Does It Do?

The CYP2C19 enzyme helps process medications like some antidepressants and stomach acid reducers.

Your Genetic Variation

You have a version of the gene (rs4244285 with GT genotype) that makes the CYP2C19 enzyme work slower than normal (this is called being an intermediate metabolizer).

What This Means for You

Antidepressants (like Citalopram and Sertraline):

• Effect: Your body processes these medicines more slowly, which can lead to higher levels in your body and increase the risk of side effects.
• What to Do: Your doctor may prescribe a lower dose to reduce side effects and will monitor how you respond to the medication.

Clopidogrel (a medication that prevents blood clots that may cause strokes or heart attacks):

• Effect: Your body may not activate clopidogrel effectively, reducing its ability to prevent clots.
• What to Do: Your doctor might consider prescribing a different medication that works better for you.

3. CYP2D6 Enzyme

What Does It Do?

The CYP2D6 enzyme helps process medications like certain pain relievers and antidepressants.

Your Genetic Variation

Based on your genetic variation (rs1135840 TT, rs61736512 TT, rs16947 TT), your CYP2D6 enzyme likely works normally.

What This Means for You

Medications Processed by CYP2D6:

• Effect: You are expected to process these medicines at a normal rate.
• What to Do: Standard doses of these medications should work well for you.

Why This Information Is Important

Understanding how your body processes medications can help your doctor:

• Choose the Right Medicine: Some medications might not work as well for you or could cause side effects.
• Determine the Best Dose: You might need a higher or lower dose than usual to get the best effect with the fewest side effects.
• Avoid Side Effects: Knowing your metabolism can prevent problems like excessive bleeding or unwanted reactions.

Next Steps

• Talk to Your Doctor: Share this information with your healthcare provider. They can use it to make informed decisions about your medications.
• Medication Adjustments: Do not change or stop any medications on your own. Always consult your doctor before making changes.

Remember: This information helps tailor your healthcare to your unique genetic makeup, ensuring you receive the most effective and safest treatments possible.

Summary of Findings

Variants Impacting Cardiovascular Drugs

1. CYP2C9 Gene (rs1799853 CT genotype)

What This Means for You

You have one normal-function allele (*1) and one reduced-function allele (*2) in the CYP2C9 gene, making you an intermediate metabolizer.

Impact on Medications

• Warfarin
  • Effect: You may metabolize warfarin more slowly than average. This means you may require a lower dose of warfarin to achieve the desired blood-thinning effect and to reduce the risk of bleeding.
  • Recommendation: If you are prescribed warfarin, your healthcare provider may consider starting you on a lower dose and will monitor your blood clotting levels (INR) closely to adjust the dose as needed.
• Irbesartan
  • Effect: This blood pressure medication may be more effective for you, potentially leading to better blood pressure control.
  • Recommendation: Standard dosing may be appropriate, but your blood pressure should be monitored to ensure optimal control.

2. CYP4F2 Gene (rs2108622 CT genotype)

What This Means for You

You have one normal-function allele and one variant allele associated with decreased enzyme activity.

Impact on Medications

• Warfarin
  • Effect: You may need a slightly higher dose of warfarin to achieve the desired effect, as the CYP4F2 variant can reduce the metabolism of vitamin K, which opposes warfarin’s action.
  • Recommendation: Your healthcare provider may adjust your warfarin dose accordingly and monitor your INR levels to ensure you are within the therapeutic range.
• Aspirin and Clopidogrel
  • Effect: You may have a decreased response to these antiplatelet medications, which are used to prevent heart attacks and strokes.
  • Recommendation: Your healthcare provider may monitor your response to these medications and consider alternative treatments if necessary.

3. KIF6 Gene (rs20455 AG genotype)

What This Means for You

You carry one copy of the risk allele (G) associated with cardiovascular disease.

Impact on Medications

• Statins (e.g., Atorvastatin, Pravastatin)
  • Effect: You may experience greater benefit from statin therapy in reducing your risk of heart disease.
  • Recommendation: Statin therapy may be particularly beneficial for you. Discuss with your healthcare provider about starting or continuing statins if appropriate.

Variants Impacting Mental Health and Pain Drugs

1. OPRM1 Gene (rs1799971 AG genotype)

What This Means for You

You have one copy of the G allele, which can influence your response to opioid medications.

Impact on Medications

• Opioids (e.g., Morphine, Fentanyl, Tramadol)
  • Effect: You may experience increased pain relief from opioids compared to individuals without this variant.
  • Recommendation: Standard opioid dosing may be effective for you, but you may be more sensitive to these medications. Your healthcare provider may monitor you for increased effectiveness and potential side effects, such as sedation or constipation.
• Side Effects
  • Effect: You may have an increased likelihood of experiencing side effects like constipation or nausea when using opioids.
  • Recommendation: Inform your healthcare provider if you experience side effects. They may adjust your dose or recommend treatments to manage side effects.
• Addiction Treatments
  • Naltrexone for Alcohol Dependence
    • Effect: You may have an increased response to naltrexone, which could be more effective in reducing alcohol cravings.
    • Recommendation: If you are being treated for alcohol dependence, naltrexone may be a suitable option. Discuss this with your healthcare provider.
  • Nicotine Dependence
    • Effect: You may have a decreased likelihood of successfully quitting smoking using nicotine replacement therapies.
    • Recommendation: Alternative smoking cessation strategies may be more effective for you. Consult your healthcare provider for personalized advice.

2. SCN1A Gene (rs2298771 TT genotype)

What This Means for You

You have two copies of the T allele, which can influence how you respond to certain seizure medications.

Impact on Medications

• Valproic Acid
  • Effect: You may experience better seizure control with valproic acid and have a lower risk of weight gain as a side effect.
  • Recommendation: Valproic acid may be an effective treatment option for epilepsy. Discuss this with your neurologist.

3. CYP2C19 Gene (rs4244285 GT genotype)

What This Means for You

You have one normal-function allele (*1) and one no-function allele (*2), making you an intermediate metabolizer of CYP2C19 substrates.

Impact on Medications

• Antidepressants (e.g., Citalopram, Sertraline)
  • Effect: You may metabolize these medications more slowly, potentially leading to higher drug levels in your body and an increased risk of side effects.
  • Recommendation: Your healthcare provider may consider starting you on a lower dose and monitor for effectiveness and side effects.
• Proton Pump Inhibitors (e.g., Omeprazole)
  • Effect: You may have higher drug levels, which could enhance effectiveness but also increase side effects.
  • Recommendation: Standard dosing may be appropriate, but your provider may monitor for side effects.

Variants Impacting Immunity and Inflammation Related Drugs

1. NAT2 Gene (rs1801280 TC genotype)

What This Means for You

You have one slow acetylator allele and one fast acetylator allele, making you an intermediate acetylator.

Impact on Medications

• Isoniazid (for Tuberculosis)
  • Effect: You may process isoniazid more slowly, which can increase the risk of liver toxicity.
  • Recommendation: If you are prescribed isoniazid, your healthcare provider may monitor your liver function tests more closely and adjust the dose if necessary.

2. ATIC Gene (rs2372536 CG genotype)

What This Means for You

You have one copy of each allele, which may influence your response to certain medications.

Impact on Medications

• Methotrexate (for Rheumatoid Arthritis)
  • Effect: You may have a decreased response to methotrexate, meaning it may be less effective in controlling your symptoms.
  • Recommendation: Your healthcare provider may consider increasing the dose of methotrexate or exploring alternative treatments to manage your condition effectively.

3. SLCO1B1 Gene (rs4149057 TC genotype)

What This Means for You

You carry one variant allele associated with altered drug transport into the liver.

Impact on Medications

• Methotrexate
  • Effect: You may have reduced clearance of methotrexate, potentially leading to higher drug levels and increased risk of side effects.
  • Recommendation: Your healthcare provider may monitor methotrexate levels and adjust your dose to minimize side effects.

Note: This information is intended to help you and your healthcare providers make informed decisions about your medications. Always consult your healthcare provider before making any changes to your medication regimen.

Personalized Pharmacogenetic Summary Table

This table provides a summary of how your genetic variations may affect your response to certain medications. It is designed to help you and your healthcare provider make informed decisions about your treatment plan.

How to Use This Table:

• Drug: The medication that may be impacted by your genetics.
• Gene: The specific gene that influences how you process the medication.
• Variant: The particular genetic variant identified in your DNA.
• Genotype: Your specific genetic makeup for that variant.
• Impact/Insight: How your genotype may affect the medication’s effectiveness or risk of side effects.
• Recommendation: Suggested actions or considerations for you and your healthcare provider.

Review this table to understand any potential adjustments or precautions that may be necessary when taking these medications. Always consult with your healthcare provider before making any changes to your medication regimen.

Drug	Gene	Variant	Genotype	Impact/Insight	Recommendation
Acetaminophen	OPRM1	rs1799971	AG	Genotype AG is associated with an increased likelihood of constipation and may require higher doses for effective pain relief compared to AA genotype.	Monitor for constipation; may require higher doses for pain control; consult healthcare provider for appropriate dosing and management.
Alfentanil	OPRM1	rs1799971	AG	Genotype AG may require higher doses of alfentanil for effective pain control and may have an increased risk of respiratory depression compared to AA genotype.	May require higher doses; monitor pain levels and respiratory function closely; adjust dosing as needed; consult anesthesiologist or pain specialist.
Aspirin	CYP4F2	rs2108622	CT	Genotype CT is associated with a decreased response to aspirinand clopidogrel, potentially reducing antiplatelet effectiveness compared to TT genotype.	May require alternative antiplatelet therapy or additional monitoring; discuss with healthcare provider for personalized treatment plan.
Atorvastatin	KIF6	rs20455	AG	Genotype AG is associated with increased benefit from atorvastatin, leading to greater reduction in cardiovascular events compared to AA genotype.	Atorvastatin may be particularly beneficial; consider as part of lipid-lowering therapy; discuss with healthcare provider.
Buprenorphine	OPRM1	rs1799971	AG	No significant association between genotype AG and response to buprenorphine; standard response expected.	Proceed with standard therapy; monitor response as per usual care; no genotype-based adjustments necessary.
Carbamazepine	SCN1A	rs2298771	TT	Genotype TT is associated with better response to carbamazepine and a reduced likelihood of drug resistance in epilepsy treatment compared to CC and CT genotypes.	Standard dosing may be effective; monitor seizure control; consult neurologist for management.
Celecoxib	CYP2C9	rs1799853	CT	Genotype CT may lead to higher plasma levels of celecoxib, increasing the risk of side effects compared to CC genotype.	Consider starting with a lower dose; monitor for adverse effects; adjust dose as necessary; consult healthcare provider.
Clopidogrel	CYP2C19	rs4244285	GT (*1/*2)	As an intermediate metabolizer, you may have reduced activation of clopidogrel, leading to decreased antiplatelet effect and increased risk of cardiovascular events compared to normal metabolizers.	Consider alternative antiplatelet agents not affected by CYP2C19 genotype (e.g., prasugrel, ticagrelor); discuss with healthcare provider.
Codeine	OPRM1	rs1799971	AG	Genotype AG may require higher doses of codeine for effective pain relief compared to AA genotype.	May require higher doses; monitor pain control and adjust dosing as needed; consult healthcare provider.
Donepezil	APOE	rs429358	TC	Presence of C allele (APOE ε4 allele) is associated with increased response to donepezil in Alzheimer’s disease compared to T allele.	Donepezil may be more effective; proceed with standard dosing; monitor cognitive function; maintain regular follow-ups with healthcare provider.
Ethambutol	NAT2	rs1801280	TC	Presence of T allele may decrease the risk of liver toxicity during tuberculosis treatment compared to C allele.	Standard monitoring for liver toxicity; proceed with standard dosing; consult healthcare provider if any signs of liver dysfunction occur.
Fentanyl	OPRM1	rs1799971	AG	Genotype AG is associated with increased response to fentanyl, potentially requiring lower dosesfor effective pain control compared to AA genotype.	May require lower doses; monitor for signs of over-sedation or respiratory depression; adjust dosing as needed; consult healthcare provider.
Fluoxetine	CYP2C19	rs17878459	GC	Presence of C allele may result in decreased sensitivity to fluoxetine, potentially reducing efficacy compared to G allele.	May require higher doses for therapeutic effect; monitor response and adjust dosing; consult healthcare provider.
Fluvoxamine	CYP2C19	rs17878459	GC	Presence of C allele may increase sensitivity to fluvoxamine, potentially leading to higher drug levels and increased risk of side effects compared to G allele.	May require lower starting dose; monitor for side effects; adjust dosing as necessary; consult healthcare provider.
Hydrocodone	OPRM1	rs1799971	AG	Genotype AG is associated with an increased risk of constipationwhen using hydrocodone compared to AA genotype.	Monitor for constipation; consider preventive measures; adjust therapy as needed; consult healthcare provider.
Hydromorphone	OPRM1	rs1799971	AG	Genotype AG is associated with increased response to hydromorphone, potentially requiring lower doses compared to AA genotype.	May require lower doses; monitor for signs of over-sedation; adjust dosing as needed; consult healthcare provider.
Indomethacin	CYP2C9	rs1799853	CT	Presence of T allele may lead to increased response to indomethacin, potentially enhancing efficacy compared to C allele.	Standard dosing may be appropriate; monitor for efficacy and side effects; consult healthcare provider.
Irbesartan	CYP2C9	rs1799853	CT	Genotype CT is associated with increased response to irbesartan, potentially leading to better blood pressure control compared to CC genotype.	Standard dosing may be effective; monitor blood pressure; adjust therapy as needed; consult healthcare provider.
Isoniazid	NAT2	rs1801280	TC	Presence of C allele may increase the risk of drug-induced liver injury when treated with isoniazid compared to T allele.	Monitor liver function tests closely; consider dose adjustment if necessary; consult healthcare provider for personalized management.
Ketoprofen	CYP2C9	rs1799853	CT	Genotype CT may be associated with increased risk of dyspepsiawhen using ketoprofen compared to CC genotype.	Monitor for gastrointestinal side effects; consider gastroprotective agents; adjust therapy as needed; consult healthcare provider.
Methadone	OPRM1	rs1799971	AG	Genotype AG may be associated with a decreased likelihood of sleep disorders and may require standard dosing in opioid use disorder treatment compared to AA genotype.	Proceed with standard dosing; monitor therapeutic response; consult healthcare provider for personalized management.
Methotrexate	ATIC	rs2372536	CG	Genotype CG may be associated with decreased response to methotrexate and folic acid, potentially reducing effectiveness in rheumatoid arthritis compared to CC genotype.	Monitor therapeutic response; may require dose adjustments; consider alternative treatments; discuss with healthcare provider.
Morphine	OPRM1	rs1799971	AG	Genotype AG may not significantly affect the risk of constipation, delirium, nausea, pruritus, or urinary retention when using morphine compared to AA genotype.	Proceed with standard therapy; monitor for side effects; no genotype-based adjustments necessary.
Naltrexone	OPRM1	rs1799971	AG	Genotype AG is associated with increased response to naltrexonein alcohol dependence, leading to better blunting of alcohol cravings compared to AA genotype.	Naltrexone may be more effective; consider as part of treatment plan; monitor response; consult healthcare provider.
Nicotine	OPRM1	rs1799971	AG	Genotype AG is associated with a decreased likelihood of successful smoking cessationusing nicotine replacement therapies compared to AA genotype.	Alternative smoking cessation strategies may be more effective; consult healthcare provider for personalized advice.
Phenytoin	CYP2C9	rs1799853	CT	Genotype CT is associated with decreased metabolism of phenytoin, leading to higher drug levels and an increased risk of side effects like ataxia and dizziness compared to CC genotype.	May require lower doses; monitor blood levels and for signs of toxicity; adjust dosing as needed; consult healthcare provider.
Pravastatin	KIF6	rs20455	AG	Genotype AG is associated with a decreased risk of coronary disease when treated with pravastatin compared to AA genotype.	Pravastatin may be particularly beneficial; consider as part of lipid-lowering therapy; discuss with healthcare provider.
Simvastatin	KIF6	rs20455	AG	Genotype AG may be associated with decreased response to simvastatin, potentially requiring adjustments in therapy compared to AA genotype.	Monitor lipid levels to assess efficacy; may require alternative statins or dose adjustments; consult healthcare provider.
Tramadol	OPRM1	rs1799971	AG	Genotype AG is associated with increased response to tramadoland an increased likelihood of nausea compared to AA genotype.	May require lower doses; monitor for side effects like nausea; adjust dosing as needed; consult healthcare provider.
Valproic Acid	SCN1A	rs2298771	TT	Genotype TT is associated with increased clinical benefit from valproic acid and a decreased likelihood of weight gain in epilepsy treatment compared to CC and CT genotypes.	Valproic acid may be particularly effective; proceed with standard dosing; monitor therapeutic response; consult neurologist for management.
Warfarin	CYP2C9	rs1799853	CT	Genotype CT indicates you are an intermediate metabolizer, leading to slower metabolism of warfarin and a higher risk of bleeding; you may require a lower dose compared to CC genotype.	May require a lower starting dose; monitor INR levels closely; adjust dosage based on INR and bleeding risk; consult healthcare provider for personalized dosing.
Warfarin	CYP4F2	rs2108622	CT	Genotype CT may require a slightly higher dose of warfarinto achieve the desired effect due to altered vitamin K metabolism compared to CC genotype.	Adjust warfarin dose accordingly; monitor INR levels to ensure therapeutic range; consult healthcare provider.
Warfarin	APOE	rs429358	TC	Presence of C allele may be associated with a decreased dose requirement of warfarin and an increased risk of hemorrhagecompared to T allele.	Consider lower starting doses; monitor INR closely; adjust dosage based on INR and bleeding risk; educate on signs of bleeding; consult healthcare provider for management.
Ziprasidone	APOE	rs429358	TC	Allele C is not associated with memory disorders when exposed to ziprasidone; standard response expected compared to T allele.	Proceed with standard dosing; monitor therapeutic response and cognitive function; no genotype-based adjustments necessary.

Conclusion

Your genetic profile suggests that you may require adjustments to certain medications to achieve the best therapeutic outcomes and minimize side effects. Specifically, you may need lower doses of drugs like warfarin and phenytoin, and you may respond differently to medications like methotrexate and certain antidepressants. It’s important to discuss these findings with your healthcare provider, who can tailor your medication regimen based on this information.

For more detailed information suitable for healthcare professionals, including pharmacists and prescribers, please refer to the online version of this report. This detailed information can assist them in making informed decisions about your medication management.

Potential Nutraceuticals Based on Your Genetic Variations

Based on your genetic data, several gene mutations may impact your health. While this information is not intended to provide medical recommendations, it may help you understand whether certain nutraceuticals could be beneficial. Always consult a qualified healthcare professional before making any changes to your supplement or health regimen.

1. LDLR Gene (Low-Density Lipoprotein Receptor)

Associated Condition

Mutations in the LDLR gene can lead to familial hypercholesterolemia, a condition characterized by elevated LDL cholesterol levels and an increased risk of cardiovascular disease.

Potential Nutraceuticals

• Plant Sterols and Stanols
  • What They Do: Reduce the absorption of cholesterol in the intestines, potentially lowering LDL cholesterol levels.
• Soluble Fiber (e.g., Psyllium)
  • What It Does: Binds cholesterol in the digestive system, aiding in its excretion.
• Omega-3 Fatty Acids
  • What They Do: Found in fish oil, omega-3s may help improve lipid profiles by reducing triglycerides and may modestly lower LDL cholesterol.
• Red Yeast Rice
  • What It Contains: Monacolin K, which is chemically identical to lovastatin, a cholesterol-lowering medication. It may help reduce LDL cholesterol levels.
• Niacin (Vitamin B3)
  • What It Does: Can lower LDL cholesterol and triglycerides while raising HDL cholesterol.

Evidence

Several studies have demonstrated the cholesterol-lowering effects of these nutraceuticals in individuals with elevated cholesterol levels. They may be particularly beneficial as additions to traditional therapies in managing hypercholesterolemia.

2. ATP8B1 Gene (ATPase Phospholipid Transporting 8B1)

Associated Conditions

Mutations in the ATP8B1 gene are linked to cholestasis disorders, such as Benign Recurrent Intrahepatic Cholestasis (BRIC) and Progressive Familial Intrahepatic Cholestasis (PFIC).

Potential Nutraceuticals

• Fat-Soluble Vitamins (A, D, E, K)
  • Why They’re Important: Cholestasis can lead to malabsorption of fat-soluble vitamins. Supplementation may help prevent deficiencies.
• S-Adenosylmethionine (SAMe)
  • What It Does: May support liver function and promote bile flow.
• Milk Thistle (Silymarin)
  • What It Does: An herbal supplement that may have liver-protective properties.

Evidence

Some clinical trials suggest these supplements might support liver function and improve symptoms in individuals with liver disorders. However, evidence specific to ATP8B1 mutations is limited.

3. VWF Gene (Von Willebrand Factor)

Associated Condition

Mutations in the VWF gene can cause von Willebrand disease, a bleeding disorder resulting from defective platelet adhesion.

Potential Nutraceuticals

• Vitamin C and Bioflavonoids
  • What They Do: May strengthen capillary walls and reduce bleeding tendencies. Bioflavonoids like rutin and hesperidin may enhance the effects of vitamin C.
• Vitamin K
  • Role: Essential for blood clotting. Use should be carefully considered under medical supervision due to its role in coagulation.

Evidence

While not a replacement for medical treatments, some studies suggest that vitamin C and bioflavonoids may support vascular health. Evidence specific to von Willebrand disease is limited and requires further research.

4. MYO7A Gene (Myosin VIIA)

Associated Condition

Mutations in the MYO7A gene are linked to Usher syndrome type 1B, characterized by hearing loss and progressive vision loss due to retinitis pigmentosa.

Potential Nutraceuticals

• Vitamin A (Retinyl Palmitate)
  • What It Does: High-dose vitamin A supplementation has been studied for slowing the progression of retinitis pigmentosa in some individuals.
• Lutein and Zeaxanthin
  • What They Do: Carotenoids that may support eye health by protecting retinal cells from oxidative damage.
• Omega-3 Fatty Acids
  • What They Do: May benefit retinal health and have been studied in relation to slowing vision loss.

Evidence

Clinical studies have explored vitamin A supplementation in retinitis pigmentosa, with some suggesting a slowed disease progression. However, high doses can have toxic effects, and supplementation should only be considered under medical supervision.

5. F5 Gene (Coagulation Factor V)

Associated Condition

Mutations such as Factor V Leiden in the F5 gene increase the risk of developing abnormal blood clots (thrombophilia).

Potential Nutraceuticals

• Omega-3 Fatty Acids
  • What They Do: May have antithrombotic properties by reducing platelet aggregation and blood viscosity.
• Garlic
  • What It Does: Suggested to have mild anticoagulant effects.
• Ginkgo Biloba
  • What It Does: May inhibit platelet-activating factor, potentially reducing clot formation.
• Vitamin E
  • What It Does: Possesses antiplatelet and antioxidant properties.

Evidence

Some studies indicate these nutraceuticals may influence blood coagulation pathways. However, they can also increase bleeding risk, especially when combined with anticoagulant medications.

6. SDHB Gene (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)

Associated Conditions

Mutations in the SDHB gene are associated with hereditary paraganglioma-pheochromocytoma syndromes, leading to the development of tumors in the nervous system.

Potential Nutraceuticals

• Antioxidants (e.g., Vitamin C, Vitamin E, Coenzyme Q10)
  • What They Do: May support mitochondrial function and protect cells from oxidative stress.
• Alpha-Lipoic Acid
  • What It Does: An antioxidant that may benefit mitochondrial health.

Evidence

While antioxidants support general cellular health, there is limited specific evidence on their effectiveness in preventing or treating tumors associated with SDHB mutations.

7. ABCA13 Gene (ATP Binding Cassette Subfamily A Member 13)

Associated Conditions

The role of ABCA13 gene mutations is not well-established but has been studied in relation to certain psychiatric disorders.

Potential Nutraceuticals

• Omega-3 Fatty Acids
  • What They Do: May support mental health by modulating neurotransmission.
• B Vitamins (e.g., B6, B12, Folate)
  • Why They’re Important: Essential for neurological function and may impact mood regulation.

Evidence

While these nutrients are essential for brain health, specific evidence linking them to ABCA13 mutations is currently lacking.

Summary

While there is evidence that certain nutraceuticals may be beneficial for individuals with specific genetic mutations, it is important to note that:

• The effectiveness of these nutraceuticals can vary between individuals.
• Nutraceuticals may complement but not replace conventional medical treatments.
• High doses or inappropriate use of supplements can have adverse effects.
• Clinical evidence may be limited or preliminary for some supplements.

Note: Before considering any nutraceuticals, please consult with a qualified healthcare professional to discuss potential benefits and risks based on your personal medical history and current treatments.

Sources

Data presented in this report have been sourced from highly curated databases such as ClinPGx, ClinVar and PharmVar. References to these databases can be found in the publications listed below. Since not all of the defining variants have been included into the variant panel used by the ancestry websites, negative finding carries less weight than positive findings.

Whirl-Carrillo et al, An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine” Clinical Pharmacology & Therapeutics (2021) Sep;110(3):563-572. doi: 10.1002/cpt.2350. Epub 2021 Jul 22. Nucleic Acids Res 2018 DOI: 10.1093/nar/gkx1153.

Landrum MJ et al., ClinVar: improving access to variant interpretations and supporting evidence. DOI 10.1093/nar/gkx1153 [doi]